Managing comorbidities in patients with chronic heart failure: first, do no harm

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Heart failure (HF) affects over 5 million US adults, with prevalence projected to increase.
• HF patients face elevated morbidity and mortality risks, often compounded by comorbidities.
• Common comorbidities include diabetes mellitus, chronic pain, arrhythmias, and depression, complicating HF management.

Purpose of the Study:

• To review the relationship between medications for common HF comorbidities and HF.
• To provide guidance on pharmacologic options requiring special consideration, monitoring, or avoidance in HF patients.
• To improve prescribing practices for enhanced patient safety and reduced HF-related morbidity and mortality.

Main Methods:

• Literature review and synthesis of current evidence.
• Analysis of medication classes used to treat diabetes, pain, arrhythmias, and depression.
• Focus on drug interactions and effects on HF pathophysiology.

Main Results:

• Certain medications for diabetes (e.g., TZDs), pain (e.g., NSAIDs), arrhythmias (e.g., non-dihydropyridine CCBs), and depression (e.g., some TCAs) can negatively impact HF.
• Specific drug mechanisms contributing to HF exacerbation are discussed.
• Recommendations for monitoring and alternative therapies are outlined.

Conclusions:

• Understanding medication risks is crucial for managing HF patients with comorbidities.
• Careful selection and monitoring of pharmacotherapy can mitigate adverse effects.
• This guidance aims to optimize treatment strategies for improved HF outcomes.